Gene Expression Map of Human Body Gives Value to Variants
In a massive project analyzing gene expression patterns among 44 human tissues from 449 people, researchers correlated genetic variation with region-specific transcriptomes.
6401 RESULTS
Sort By:
In a massive project analyzing gene expression patterns among 44 human tissues from 449 people, researchers correlated genetic variation with region-specific transcriptomes.
A single-nucleotide polymorphism near the TMEM106b locus boosts expression of the gene, which is linked to frontotemporal dementia.
Neuronal plasticity falters with Alzheimer’s disease, but noninvasive stimulation strengthens it. Meanwhile, mini-jolts inside the brain improve face recognition in epilepsy patients.
The agency’s request for information seeks feedback on the nature and value of the prize. Help shape it!
Souvenaid missed its primary cognitive endpoint in the two-year trial, but reduced brain atrophy and slowed functional decline.
Expressed in the brains of mice, a secreted form of the anti-aging protein, klotho, protects from an age-related decline in memory.
Signals from neuron EphB1 receptors boost neuroprotective functions in astrocytes. This line of communication appears cut in ALS.
The philanthropist today announced a $50 million investment in the U.K.’s Dementia Discovery Fund, which supports startups developing innovative treatments.
In people with ALS, researchers identified 39 new genetic variations in RNA-binding proteins that may influence the disease. Such information could inform future pharmacogenomics treatment.
A case study describes amyloidosis in a 39-year-old homozygous for a TREM2 mutation, but experts question the interpretation.
Small molecules that stabilize G-quadruplexes cut C9ORF72 RNA and protein deposits in half.
10th CTAD: Finally, Alzheimer’s Field Is Serious About Prevention Trials At CTAD, Tau PET Emerges as Favored Outcome Biomarker for Trials Automated CSF Tests: Check. Blood Tests: In the Works Cognitive Testing Is Getting Faster and Better Don’t Be an Enro
Alzheimer’s science has undergone a paradigm shift toward the disease’s silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?
Two complementary studies find that ApoE4 has little influence on plaques once they are present.
Tau’s apparent lockstep with cognitive decline dominated the PET conversation. Piramal flaunted data, and Merck/Cerveau are close behind. A first stab at imaging synapses in the hippocampus drew notice, too.